The technology, named Instacoat EHP 250, is a single polymer (PVA) based fully aqueous coating system – the fourth generation in the firm’s line of products.
It has the ability to spray rapidly with a high solid content of 25 to 30 per cent, and is aimed at immediate release formulations in solid oral dosage forms.
The film is also formulated so that when reconstituted it does not become viscous.
Suresh Pareek, Ideal Cures founder and managing director, told in-PharmaTechnologist: “There is no similar system in the market today. Besides everything else it does, it also has unique properties of moisture barrier for hygroscopic drugs.”
He added that the EHP 250 – following previous efforts EMB, EEN and EHA – would boost productivity between 25 to 50 per cent, depending on the coating system already in place.
The company provide the coating products in ready-to-use form, then follow up with an after sales service.
Dario Luini, EMEA area manager for Ideal Cures Europe, told in-PharmaTechnologist: “We provide a pre and post sales technical support to our customers, as well as analytical and regulatory support. We have a team of experts dedicated to QC and regulatory affairs.”
“Ideal Cure follows our customers from the first R&D sample to the full scale-up activities – from laboratory batch size to production scale.”
As for the possibility of licensing the product to other companies, Pareek said Ideal Cures is not interested at present.
He added: “However we are open and looking to license our multi color coating technology to pharma manufacturers in USA and Europe for their new products.”